As Vice President of Scientific Affairs, Dr. Morimoto is directly responsible for developing and deploying scientific, regulatory and medical expertise and advice to various biotech and emerging pharmaceutical companies. He works closely with subject matter experts across all Celerion business units to provide consulting services and timely input on drug development programs.
Prior to joining Celerion, he was Vice President of Drug Development at Allon Therapeutics, where his responsibilities included management of early clinical research, nonclinical and manufacturing activities for the davunetide drug development program. Dr. Morimoto also directed the chronic/neuropathic pain program at NeuroMed Technologies. He started his career on the faculty in the Chemistry Department at Purdue University where his independent research focused on the regulation of signal transduction and second messenger production.
Bruce earned his doctorate in biochemistry from the University of California, Los Angeles (UCLA), and completed post doctorate research at University of California, Berkeley. He has a Bachelor of Science degree in biochemistry from the University of California, Los Angeles (UCLA).